NRAS and myelodysplastic syndrome: Though, the gene mutation frequency of SRSF2 (23.5% vs. 14%), U2AF1 (16.2% vs. 11.6%), ASXL1 (13.2% vs. 4.7%), RUNX1 (13.2% vs. 4.7%), ATM (7.4% vs. 4.7%) and NRAS (5.9% vs. 4.7%) was more in high risk MDS patients, there was no significant difference was observed between high and low risk groups (p > 0.05) (Table 3).